Last edition
News about "BioLineRx "
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
BioLineRx | 09/07/2026 | By News Bureau
BioLineRx Gets USPTO Allowance of New Composition of Matter Patent on Motixafortide
The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in the US through December 2041.
BioLineRx | 18/10/2024 | By Aishwarya | 529
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy